Images List Premium Download Classic

Steatohepatitis

Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Tiopronin prodrugs, pharmaceutical compositions thereof, and methods of use
Shenzhen Hightide Biopharmaceutical, Ltd.
May 11, 2017 - N°20170129867

Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of ...
Industry-academic Cooperation Foundation, Yonsei University
May 04, 2017 - N°20170121380

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Thyromimetics for the treatment of fatty liver diseases
Metabasis Therapeutics, Inc.
April 27, 2017 - N°20170112864

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Hadasit Medical Research Services And Development Ltd.
April 20, 2017 - N°20170105996

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
Uses of mito-ob transgenic mice
University Of Manitoba
March 30, 2017 - N°20170089888

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes. It has been discovered that these mice also spontaneously develop nonalcoholic steatohepatitis (nash) and hepatocarcinogenesis over time. Also described is a mutant mito-ob mouse that develops lymphadenopathy and histiocytosis.
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel compounds as diacylglycerol acyltransferase inhibitors
Glaxosmithkline Llc
March 23, 2017 - N°20170081342

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of ...
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
Glaxosmithkline Llc
March 23, 2017 - N°20170081280

Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial ...
Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use
Glaxosmithkline Llc
March 23, 2017 - N°20170081279

Cysteamine prodrugs, pharmaceutical compositions comprising the cysteamine prodrugs, and methods of using cysteamine prodrugs and pharmaceutical compositions thereof for treating eye, kidney, liver, metabolic, and neurological disorders such as cystinosis, cystinuria, non-alcoholic steatohepatitis, batten disease, leigh syndrome, and huntington's disease.
Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Glaxosmithkline Llc
March 16, 2017 - N°20170071968

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 16, 2017 - N°20170042964

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a nuclear transport modifier may ...
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
February 09, 2017 - N°20170037043

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their ...
Compositions and methods for treating non-alcoholic steatohepatitis
Mochida Pharmaceutical Co., Ltd.
January 12, 2017 - N°20170007566

Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (nash).
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Glucagon and glp-1 co-agonist compounds
Eli Lilly And Company
December 22, 2016 - N°20160368960

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).
Lysosomal acid lipase therapy for nafld and related diseases
Children's Hospital Medical Center
December 22, 2016 - N°20160367645

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics
The Regents Of The University Of California
December 15, 2016 - N°20160360735

The invention provides a non-human animal model for non-alcoholic steatohepatitis (nash)-induced heptocellular carcinoma, methods of screening for agents for treating heptocellular carcinoma, methods of screening for targets useful in suppressing nash progression to heptocellular carcinoma, methods of treating heptocellular carcinoma, and compositions for treating the same.
Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
The Regents Of The University Of California
December 08, 2016 - N°20160354387

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Ketohexokinase (khk) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
November 24, 2016 - N°20160340679

The present invention relates to rnai agents, e. G., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e. G., liver disease (e. G., fatty liver, steatohepatitis), dyslipidemia (e. G., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), ...
Differential diagnosis of liver disease
The Regents Of The University Of California
October 20, 2016 - N°20160305925

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls. Specifically, the invention relates to ...
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
September 29, 2016 - N°20160279157

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
Volant Holdings Gmbh
September 15, 2016 - N°20160263131

The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of hepatic fibrosis, including hepatic fibrosis associated with hepatitis, hepatic fibrosis associated with hepatitis b infection, and non-alcoholic steatohepatitis (nash), and pharmaceutical compositions comprising such alpha helix mimetic ...
Loading